Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
BIO-WORKS TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
15.07. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB announces outcome from exercise of warrants of series TO 2. Exercise period 3 of 11 | 1 | Cision News | ||
11.07. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives SEK 5.5 Million Order from Global Pharmaceutical Company | 1 | Cision News | ||
01.07. | BIO-WORKS TECHNOLOGIES AB: Today is the first day of the third exercise period for Bio-Works Technologies AB's warrants of series TO 2 | 2 | Cision News | ||
15.05. | BIO-WORKS TECHNOLOGIES AB: Bio-Works receives WorkBeads order worth SEK 2.5 million | 1 | Cision News | ||
15.05. | BIO-WORKS TECHNOLOGIES AB: Resolutions passed at Bio-Works Technologies' annual general meeting 2025 | 16 | Cision News | ||
15.05. | BIO-WORKS TECHNOLOGIES AB: Bio-Works reports first quarter 2025 | 1 | Cision News | ||
29.04. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives Order Worth SEK 2.4 Million from New European Customer in Vaccine Production | 1 | Cision News | ||
15.04. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB announces outcome from exercise of warrants of series TO 2. Exercise period 2 of 11 | 1 | Cision News | ||
14.04. | BIO-WORKS TECHNOLOGIES AB: Bio-Works receives SEK 12 million order from global pharmaceutical company - delivery scheduled for 2026 | 3 | Cision News | ||
01.04. | BIO-WORKS TECHNOLOGIES AB: Today is the first day of the second exercise period for Bio-Works Technologies AB's warrants of series TO 2 | 2 | Cision News | ||
27.03. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives New Orders for Custom GoBio Columns for the U.S. Gene Therapy Market | 2 | Cision News | ||
26.02. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives Order for WorkBeads Worth 2.65 Million SEK | 2 | Cision News | ||
21.02. | BIO-WORKS TECHNOLOGIES AB: Bio-Works publishes year-end report Q4 2024 | 1 | Cision News | ||
14.02. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies Doubles Production Capacity to Meet Growing Demand | 5 | Cision News | ||
10.02. | BIO-WORKS TECHNOLOGIES AB: Bio-Works receives a third follow-up order for WorkBeads affimAb worth SEK 4.0 million | 1 | Cision News | ||
31.01. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives Follow-Up Order for WorkBeads affimAb Worth 4.6 MSEK | 1 | Cision News | ||
07.08.24 | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.08.2024 | 1.094 | Xetra Newsboard | Das Instrument LY10 AU000000LLO8 LION ONE METALS CDIS EQUITY wird cum Kapitalmassnahme gehandelt am 07.08.2024 und ex Kapitalmassnahme am 08.08.2024 The instrument LY10 AU000000LLO8 LION ONE METALS... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 44,080 | -0,46 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 48 auf 50 Euro angehoben und die Einstufung auf "Buy" belassen. Analyst Harry Gillis "diagnostiziert" eine defensive... ► Artikel lesen | |
EVOTEC | 7,446 | +0,62 % | ÜBERNAHMEFANTASIE! Barrick Mining, Evotec, Desert Gold Aktie | Wie die hohen Preise hält sich auch die Übernahmefantasie im Goldsektor. Als Kandidat wird immer wieder Desert Gold genannt. Mit der spannenden Akquisition in Westafrika hat der Explorer diversifiziert... ► Artikel lesen | |
BIONTECH | 98,15 | +1,71 % | BioNTech Aktie: In welche Richtung wird es gehen? | © Foto: fn SymbolbildDas deutsche Biotech-Unternehmen BioNTech steht vor einer großen Veränderung. Die erfolgreiche Zeit mit Corona-Impfstoffen geht stetig weiter zu Ende. Jetzt arbeitet das Mainzer... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 38,080 | +5,92 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Completion of Enrollment for HARBOR, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory ... | -- Topline data readout from HARBOR study anticipated in Q2 2026 ---- Marketing application submissions for del-desiran including in U.S., EU and Japan anticipated... ► Artikel lesen | |
NUVALENT | 79,18 | 0,00 % | Nuvalent, Inc.: Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naïve ALK-positive NSCLC | CAMBRIDGE, Mass., July 21, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted... ► Artikel lesen | |
REPLIMUNE | 6,100 | +87,12 % | Replimune rebounds despite analyst downgrades on FDA rejection | ||
RECURSION PHARMACEUTICALS | 6,095 | +2,44 % | Recursion Pharmaceuticals: Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th | ||
PTC THERAPEUTICS | 42,000 | +1,94 % | XFRA BH3: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILPTC THERAPEUTICS... ► Artikel lesen | |
ARCELLX | 70,00 | 0,00 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
SAREPTA THERAPEUTICS | 16,075 | +17,29 % | Biotech im Brennpunkt: Sarepta-Aktie bei 11?€ | Die Aktie von Sarepta Therapeutics notiert aktuell bei 11 und bleibt einer der volatilsten Titel im Biotech-Sektor. Nach einer Reihe von Schlagzeilen rund um Kooperationen, FDA-Untersuchungen und Analystenherabstufungen... ► Artikel lesen | |
MBX BIOSCIENCES | 14,960 | 0,00 % | Oppenheimer reiterates Outperform rating on MBX Biosciences stock ahead of Phase 2 data | ||
ARCUTIS BIOTHERAPEUTICS | 14,980 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen | |
STRUCTURE THERAPEUTICS | 17,810 | 0,00 % | Structure Therapeutics Inc. - 8-K, Current Report | ||
MODERNA | 28,350 | +0,25 % | Aktie von Moderna heute am Aktienmarkt gefragt (28,74 €) | An der US-amerikanischen Börse notiert der Anteilsschein von Moderna derzeit etwas fester. Zuletzt zahlten Investoren für das Papier 28,74 Euro. Die Aktie von Moderna verzeichnet zur Stunde einen Wertanstieg... ► Artikel lesen | |
NOVAVAX | 6,180 | +1,76 % | Novavax, Inc.: Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study | Peer-reviewed data shows Novavax's H5N1 vaccine candidate demonstrated immunogenicity against currently circulating variants following either single or two-dose... ► Artikel lesen |